麦克森药物批发（MCK）今日盘中股价大幅上涨5.84%，引起市场关注。
消息面上，行业龙头卡地纳健康因特药需求激增而上调年度利润预期，提振了整个药品分销板块的情绪。据报道，卡地纳健康、Cencora和麦克森等药品分销商正抓住治疗癌症和自身免疫性疾病等高利润特药需求激增的浪潮，同时也受益于重磅药专利悬崖带来的仿制药顺风。
分析师指出，尽管医疗保健服务市场存在波动，但对药品分销商的盈利前景持积极态度，理由是其估值偏低且增长前景强劲。行业整体向好的趋势，可能是推动麦克森股价上涨的重要因素。
麦克森药物批发（MCK）今日盘中股价大幅上涨5.84%，引起市场关注。
消息面上，行业龙头卡地纳健康因特药需求激增而上调年度利润预期，提振了整个药品分销板块的情绪。据报道，卡地纳健康、Cencora和麦克森等药品分销商正抓住治疗癌症和自身免疫性疾病等高利润特药需求激增的浪潮，同时也受益于重磅药专利悬崖带来的仿制药顺风。
分析师指出，尽管医疗保健服务市场存在波动，但对药品分销商的盈利前景持积极态度，理由是其估值偏低且增长前景强劲。行业整体向好的趋势，可能是推动麦克森股价上涨的重要因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.